These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 16522674)
1. The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey. Aletaha D; Machold KP; Nell VP; Smolen JS Rheumatology (Oxford); 2006 Sep; 45(9):1133-9. PubMed ID: 16522674 [TBL] [Abstract][Full Text] [Related]
2. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents. Pincus T; Richardson B; Strand V; Bergman MJ Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-47-54. PubMed ID: 25365089 [TBL] [Abstract][Full Text] [Related]
3. Discordance and accordance between patient's and physician's assessments in rheumatoid arthritis. Furu M; Hashimoto M; Ito H; Fujii T; Terao C; Yamakawa N; Yoshitomi H; Ogino H; Ishikawa M; Matsuda S; Mimori T Scand J Rheumatol; 2014; 43(4):291-5. PubMed ID: 24650255 [TBL] [Abstract][Full Text] [Related]
4. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Studenic P; Radner H; Smolen JS; Aletaha D Arthritis Rheum; 2012 Sep; 64(9):2814-23. PubMed ID: 22810704 [TBL] [Abstract][Full Text] [Related]
5. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort. Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE; Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035 [TBL] [Abstract][Full Text] [Related]
6. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria? El Miedany Y; Youssef SS; El Gaafary M J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918 [TBL] [Abstract][Full Text] [Related]
7. Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers. Chandrashekara S; Priyanka BU Int J Rheum Dis; 2013 Jun; 16(3):291-6. PubMed ID: 23981750 [TBL] [Abstract][Full Text] [Related]
8. Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level. Riazzoli J; Nilsson JÅ; Teleman A; Petersson IF; Rantapää-Dahlqvist S; Jacobsson LT; van Vollenhoven RF Rheumatology (Oxford); 2010 Nov; 49(11):2098-103. PubMed ID: 20615918 [TBL] [Abstract][Full Text] [Related]
9. Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment. Kaneko Y; Kuwana M; Kondo H; Takeuchi T J Rheumatol; 2014 Jun; 41(6):1061-6. PubMed ID: 24786932 [TBL] [Abstract][Full Text] [Related]
10. Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. Ranganath VK; Elashoff DA; Khanna D; Park G; Peter JB; Paulus HE; J Rheumatol; 2005 Jun; 32(6):1040-2. PubMed ID: 15940764 [TBL] [Abstract][Full Text] [Related]
11. The association of clinical parameters and ultrasound verified inflammation with patients' and physicians' global assessments in psoriatic arthritis. Lackner A; Duftner C; Ficjan A; Gretler J; Hermann J; Husic R; Graninger WB; Dejaco C Semin Arthritis Rheum; 2016 Oct; 46(2):183-189. PubMed ID: 27373500 [TBL] [Abstract][Full Text] [Related]
12. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. Crowson CS; Rahman MU; Matteson EL J Rheumatol; 2009 Aug; 36(8):1606-10. PubMed ID: 19531760 [TBL] [Abstract][Full Text] [Related]
13. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. Castrejón I; Dougados M; Combe B; Guillemin F; Fautrel B; Pincus T J Rheumatol; 2013 Apr; 40(4):386-93. PubMed ID: 23378463 [TBL] [Abstract][Full Text] [Related]
14. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413 [TBL] [Abstract][Full Text] [Related]
15. The Swedish early psoriatic arthritis register-- 2-year followup: a comparison with early rheumatoid arthritis. Lindqvist UR; Alenius GM; Husmark T; Theander E; Holmström G; Larsson PT; J Rheumatol; 2008 Apr; 35(4):668-73. PubMed ID: 18278834 [TBL] [Abstract][Full Text] [Related]
16. High dose chemotherapy and hematopoietic stem cell transplantation: a study of treatment preference in patients with rheumatoid arthritis and rheumatologists. Verburg RJ; Mahabali SD; Stiggelbout AM; Sont JK; van Laar JM J Rheumatol; 2002 Aug; 29(8):1653-8. PubMed ID: 12180724 [TBL] [Abstract][Full Text] [Related]
17. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Felson DT; Smolen JS; Wells G; Zhang B; van Tuyl LH; Funovits J; Aletaha D; Allaart CF; Bathon J; Bombardieri S; Brooks P; Brown A; Matucci-Cerinic M; Choi H; Combe B; de Wit M; Dougados M; Emery P; Furst D; Gomez-Reino J; Hawker G; Keystone E; Khanna D; Kirwan J; Kvien TK; Landewé R; Listing J; Michaud K; Martin-Mola E; Montie P; Pincus T; Richards P; Siegel JN; Simon LS; Sokka T; Strand V; Tugwell P; Tyndall A; van der Heijde D; Verstappen S; White B; Wolfe F; Zink A; Boers M Ann Rheum Dis; 2011 Mar; 70(3):404-13. PubMed ID: 21292833 [TBL] [Abstract][Full Text] [Related]
18. Minimal disease activity for rheumatoid arthritis: a preliminary definition. Wells GA; Boers M; Shea B; Brooks PM; Simon LS; Strand CV; Aletaha D; Anderson JJ; Bombardier C; Dougados M; Emery P; Felson DT; Fransen J; Furst DE; Hazes JM; Johnson KR; Kirwan JR; Landewé RB; Lassere MN; Michaud K; Suarez-Almazor M; Silman AJ; Smolen JS; Van der Heijde DM; van Riel PL; Wolfe F; Tugwell PS J Rheumatol; 2005 Oct; 32(10):2016-24. PubMed ID: 16206362 [TBL] [Abstract][Full Text] [Related]
19. Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. Ton E; Bakker MF; Verstappen SM; Ter Borg EJ; van Albada-Kuipers IA; Schenk Y; van der Veen MJ; Bijlsma JW; Jacobs JW; J Rheumatol; 2012 Jan; 39(1):22-7. PubMed ID: 22002014 [TBL] [Abstract][Full Text] [Related]
20. Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. Yazici Y; Bergman M; Pincus T J Rheumatol; 2008 Apr; 35(4):603-9. PubMed ID: 18322993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]